Cardinal aligns manufacturing units
Executive Summary
Cardinal Health names David Schlotterbeck to the new position of chief executive officer of pharmaceutical and medical products with oversight of the company's manufacturing businesses. Previously responsible for the Clinical Technologies & Services unit, Schlotterbeck is now also responsible for Cardinal's Pharmaceutical Technologies & Services and Medical Products Manufacturing segments. "The new structure will foster a uniform approach to lean manufacturing and Six Sigma initiatives, and common processes for innovation, research and development, and sourcing," Cardinal said. The change is not part of the wholesaler's restructuring initiative, which began in late 2004...
You may also be interested in...
QUOTED. 19 April 2021. Jeff Shuren & William Maisel
Two top officials in the US FDA’s device center are warning of delays in the agency’s review of submissions for new products that aren’t directly tied to the coronavirus pandemic.
Breakthrough Therapy Designations At US FDA Stay Sluggish In 2021
With 12 new BTDs announced so far this year, 2021 is on pace to match the COVID-19-depressed total number of designations in 2020. Here’s a breakdown of the candidates that have received the designation.
Half Of US FDA’s Breakthrough Therapy Designations Have Resulted In Approval
Popular expedited review program results in a higher approval rate than the related fast track designation, but the COVID-19 era is seeing a drop in designations and a rise in complete response letters for BTD programs.